- Home
- SURG vs EQ Comparison
SURG vs EQ Comparison
Compare SURG & EQ Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- SURG
- EQ
- Stock Information
- Founded
- SURG 2006
- EQ 2017
- Country
- SURG United States
- EQ United States
- Employees
- SURG N/A
- EQ N/A
- Industry
- SURG Advertising
- EQ Biotechnology: Pharmaceutical Preparations
- Sector
- SURG Consumer Discretionary
- EQ Health Care
- Exchange
- SURG Nasdaq
- EQ Nasdaq
- Market Cap
- SURG 31.3M
- EQ 31.1M
- IPO Year
- SURG N/A
- EQ 2018
- Fundamental
- Price
- SURG $1.37
- EQ $0.88
- Analyst Decision
- SURG Buy
- EQ Buy
- Analyst Count
- SURG 2
- EQ 2
- Target Price
- SURG $8.50
- EQ $5.00
- AVG Volume (30 Days)
- SURG 118.6K
- EQ 2.2M
- Earning Date
- SURG 03-11-2025
- EQ 03-24-2025
- Dividend Yield
- SURG N/A
- EQ N/A
- EPS Growth
- SURG N/A
- EQ N/A
- EPS
- SURG N/A
- EQ N/A
- Revenue
- SURG $83,602,653.00
- EQ $45,914,000.00
- Revenue This Year
- SURG N/A
- EQ $4.77
- Revenue Next Year
- SURG $59.69
- EQ N/A
- P/E Ratio
- SURG N/A
- EQ N/A
- Revenue Growth
- SURG N/A
- EQ 7.70
- 52 Week Low
- SURG $1.33
- EQ $0.49
- 52 Week High
- SURG $8.05
- EQ $3.25
- Technical
- Relative Strength Index (RSI)
- SURG 35.64
- EQ 58.42
- Support Level
- SURG $1.37
- EQ $0.85
- Resistance Level
- SURG $1.55
- EQ $0.98
- Average True Range (ATR)
- SURG 0.08
- EQ 0.10
- MACD
- SURG 0.00
- EQ 0.01
- Stochastic Oscillator
- SURG 18.18
- EQ 62.50
About SURG SurgePays Inc.
Surgepays Inc is a fintech company focused on the underbanked community. It provides services to financial technology, telecommunications, and digital media companies. Its operating segment includes Mobile Virtual Network Operators that provide mobile broadband (internet connectivity), voice and SMS text messaging to both subsidized and direct retail prepaid customers through SurgePhone Wireless, LLC and Torch Wireless, LLC; Comprehensive Platform Services provide financial technology and a wireless top-up platform to independently owned convenience stores throughout the country; Lead Generation is a generation and case management solutions company serving law firms in the mass tort industry; and Others. It generates the revenue from Mobile Virtual Network Operator segment.
About EQ Equillium Inc.
Equillium Inc is a biotechnology developing therapies to treat severe autoimmune and inflammatory disorders. Its pipeline includes itolizumab, a first-in-class antibody targeting the CD6-ALCAM pathway which plays a key role in the modulation of effector T cells - currently in a Ph 3 study for patients with acute graft-versus-host disease and a Ph 1b study for patients with lupus nephritis. EQ101, a first-in-class cytokine inhibitor that selectively targets IL-2, IL-9, and IL-15 is Ph2-ready and expected to begin enrolling patients in an alopecia areata study in 2H 2022. EQ102, a cytokine inhibitor that selectively targets IL-15 and IL-21, is ready for clinical development and expected to begin enrolling patients in a Ph 1study including patients with celiac disease.